Antiepileptogenesis After Stroke: Assessing the Impact of Eslicarbazepine Acetate on Seizure Prevention
Introduction: The Unmet Need in Post-Stroke Care
Post-stroke epilepsy (PSE) remains one of the most debilitating long-term complications of both ischemic and hemorrhagic strokes. While acute symptomatic seizures occur within the first week of a vascular event, the development of chronic epilepsy involves a complex biological process known as antiepileptogenesis. Currently, clinical guidelines do not recommend the prophylactic use of antiseizure medications (ASMs) to prevent epilepsy, primarily due to a lack of evidence that current drugs can alter the underlying disease course rather than merely suppressing symptoms.
Eslicarbazepine acetate (ESL), a once-daily, voltage-gated sodium channel blocker that targets the inactivated state of the channel, has shown promise in preclinical models for its potential neuroprotective and antiepileptogenic properties. The BIA-2093-213 trial represents a significant step in determining whether early intervention with ESL can modify the risk of unprovoked seizures in high-risk patients.
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.